9,341 Shares in Pfizer Inc. $PFE Bought by Seamount Financial Group Inc.

Seamount Financial Group Inc. bought a new stake in Pfizer Inc. (NYSE:PFE) during the second quarter, Holdings Channel.com reports. The firm bought 9,341 shares of the biopharmaceutical company’s stock, valued at approximately $226,000.

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the 1st quarter valued at about $27,000. North Capital Inc. acquired a new stake in shares of Pfizer in the first quarter valued at approximately $28,000. Bayforest Capital Ltd bought a new stake in shares of Pfizer during the first quarter valued at approximately $28,000. Horizon Financial Services LLC bought a new stake in shares of Pfizer during the first quarter valued at approximately $35,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer during the first quarter worth approximately $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Finally, Bank of America raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.41.

Pfizer Trading Down 3.4%

Shares of Pfizer stock opened at $26.45 on Tuesday. The business has a fifty day simple moving average of $24.72 and a 200-day simple moving average of $24.12. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The firm has a market cap of $150.38 billion, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the previous year, the business earned $0.60 earnings per share. Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.